Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner. 2004

Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
Department of Surgery, Shiga University of Medical Science, Seta-tsukinowa, Otsu 520-2192, Japan. konbat@med.kagawa-u.ac.jp

We previously reported that 90K/Mac-2 binding protein (M2BP) is highly expressed in lung cancer and that M2BP-specific immunity was observed in many patients with lung cancer. These findings suggested the possibility of using M2BP as a target antigen in cancer immunotherapy. In this study, we selected 11 peptides derived from M2BP with an HLA-A24 binding motif and analyzed their ability to induce M2BP-specific cytotoxic T lymphocytes (CTL). CTLs were generated with the M2BP-derived peptides from peripheral blood CD8-positive T lymphocytes of HLA-A24-positive healthy donors in multiple in vitro stimulations. Two CTLs, one induced with M2BP(241-250) (GYCASLFAIL) and the other with M2BP(568-576) (GFRTVIRPF), produced interferon-gamma in response to HLA-A24-positive TISI cells pulsed with the same peptide used for the in vitro stimulation. Although the CTLs induced with M2BP(241-250) reacted with both peptide-pulsed TISI cells and BT20 cells expressing both M2BP and HLA-A24, the CTLs induced with M2BP(568-576) did not react with BT20 cells. The cytokine production was blocked by antibodies against HLA class I in CTLs induced using M2BP(241-250), but not in CTLs induced using M2BP(568-576). These findings suggest that M2BP(241-250) is naturally processed from the native M2BP molecule in cancer cells and recognized by M2BP-specific CTLs in an HLA-A24 restriction. An M2BP-derived CTL epitope with an HLA-A24 binding motif was identified for the first time in this study, and it is expected to be useful as a target antigenic epitope in clinical immunotherapy for lung cancer.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
August 2001, World journal of gastroenterology,
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
January 2005, Microbiology and immunology,
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
January 2001, Viral immunology,
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
February 2006, Acta biochimica et biophysica Sinica,
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
November 1999, Journal of immunology (Baltimore, Md. : 1950),
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
May 1999, International journal of cancer,
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
February 1988, Journal of immunology (Baltimore, Md. : 1950),
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
December 2003, Immunology letters,
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
August 1995, Journal of immunology (Baltimore, Md. : 1950),
Keiichi Kontani, and Koji Teramoto, and Yoshitomo Ozaki, and Takuya Fujita, and Noriaki Tezuka, and Satoru Sawai, and Hiroyoshi Watanabe, and Shozo Fujino, and Hiroyasu Yokomise, and Iwao Ohkubo
March 2000, Japanese journal of clinical oncology,
Copied contents to your clipboard!